MPL W515L is uncommon in myeloproliferative diseases but is associated with abnormal STAT5 activation similar to that seen with JAK2 V617F

被引：0
|
作者：
Schade, A. E. [1 ]
Szpurka, H. [1 ]
Bak, B. [1 ]
Maciejewski, J. P. [1 ]
Hsi, E. D. [1 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
来源：
MODERN PATHOLOGY | 2007年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1188
引用
收藏
页码：259A / 259A
页数：1
相关论文
共 50 条
  • [21] The V617F JAK2 mutation inmyelodysplastic/myeloproliferative diseases is associated with marked thrombocytosis
    Billiet, J.
    Nollet, F.
    Van Droogenbroeck, J.
    Hidajat, M.
    Van Hoof, A.
    Criel, A.
    Selleslag, D.
    ACTA CLINICA BELGICA, 2006, 61 (02): : 108 - 108
  • [22] Expression of phosphorylated STAT5 in the putative stem cell population of JAK2 V617F transformed myeloproliferative neoplasms
    Hadzijusufovic, E.
    Keller, A.
    Schur, F.
    Cerny-Reiterer, S.
    Sadovnik, I
    Pecnard, E.
    Gouilleux, F.
    Valent, P.
    ONKOLOGIE, 2013, 36 : 288 - 288
  • [23] The V617F JAK2 mutation is uncommon in cancers and mutations in STAT5A, STAT5B and the JAK family genes do not account for V617F negative myeloproliferative disorders.
    Baxter, JE
    Scott, LM
    Campbell, PJ
    Todd, T
    Stephens, P
    Edkins, S
    Wooster, R
    Stratton, MR
    Futreal, AP
    Green, AR
    BLOOD, 2005, 106 (11) : 731A - 731A
  • [24] Detection of Myeloproliferative Leukemia W515L/K Mutation in JAK2v617F-Negative Myeloproliferative Neoplasms
    Punia, Jyotinder Nain
    Meng, Xiuling
    Zhuang, Yi
    Sayedian, Farzaneh
    Crisan, Domnita
    Maine, Gabriel
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2010, 134 (04) : 664 - 664
  • [25] Correction to: Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5
    Sameer Ahamd Guru
    Mamta P. Sumi
    Rashid Mir
    Ajaz Ahmad Waza
    Musadiq Ahmad Bhat
    Mariyam Zuberi
    Promod Lali
    Alpana Saxena
    Human Cell, 2020, 33 : 1334 - 1334
  • [26] JAK-STAT PATHWAY IN MYELOPROLIFERATIVE NEOPLASMS: FROM JAK2 V617F TO CALRETICULIN MUTANTS
    Constantinescu, S. N.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 : 31 - 31
  • [27] Molecular mimicry in the chronic myeloproliferative disorders: Reciprocity between JAK2 V617F genotype and Mpl expression
    Moliterno, AR
    Williams, DM
    Rogers, O
    Spivak, JL
    BLOOD, 2005, 106 (11) : 983A - 983A
  • [28] Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression
    Moliterno, Alison R.
    Williams, Donna M.
    Rogers, Ophelia
    Spivak, Jerry L.
    BLOOD, 2006, 108 (12) : 3913 - 3915
  • [29] UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation
    Szpurka, H.
    Gondek, L. P.
    Mohan, S. R.
    Hsi, E. D.
    Theil, K. S.
    Maciejewski, J. P.
    LEUKEMIA, 2009, 23 (03) : 610 - 614
  • [30] UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation
    H Szpurka
    L P Gondek
    S R Mohan
    E D Hsi
    K S Theil
    J P Maciejewski
    Leukemia, 2009, 23 : 610 - 614
12345